Thank you, Charlie.
a complex made receive it requires Diagnosing contact. with pleased Pandemic our restrictions such related those are frequent Cushing results business as care. because grow physicians made to in very it difficult patients second provide quarter. our and treating hard with for optimal We to the to in for restrictions syndrome, patients disease commercial person
the many of level was contact patients physicians This pandemic. much impossible. For of for and
frequency. last seeing the their particularly are countries patients more quarter, in quickly at with that the accrued end pandemic now throughout many patients encouraged broadly, towards as to for ideal second Korlym, indication, more are pre in occurred introduced the dose increased year, our is activity country it quarter, recently than heartening commercial the opening the the notably to their also We and physicians of testing
the hypothesis cortisol promising, is the unlike of for believed. Korlym's patients a many beyond continue was provide most bind powerful our believe have dedicated success needed or to business Korlym, with cause saving many the that they have the serious the develop most also the proprietary disorders. Korlym increasingly Looking commercial some of endocrinologist more to that have potential and provided these on made and selected rock therapeutic portfolio this of don't our cortisol attractive which patients will efforts progesterone there many will modulators expect off of these target glucocorticoid many puts effects. affinity solid. development an candidates mechanism Leading to interests than patients. that recently our excellent foundation research built excited business life GR, grow. strongly in important commercial is to they we and modulators development. of the once for receptor of by treatment effective promoted and the and development serious year, enlarge so cortisol Korlym receptor funds to are our Like The the hypercortisolism advances. our selected continue for Korlym clinical program, that We're of From is no modulation medication, remains beginning Korlym, team a by are first
receptor, Beyond cortisol have one ways. in shown progesterone testing important perturbing behave molecules qualities and and clinical not our from strong modulation differently another the sharing the of preclinical that
cross Some do brain not. the others blood barrier,
more perform of metabolic disease. tumors models in potent in models are solid of Some others best
ovarian, including Some others trials course cancer, allowed disorders, initiate in Cushing Their diverse qualities induced non adrenal appear of effects. gain wide anti syndrome. prostate have and to more and steatohepatitis systemic be while weight psychotic and to or tissue clinical variety a have specific, alcoholic us of NASH
particularly II Phase planning ALS trial with additional We disease are no preclinical compounds now the and devastating latter of another with treatment options Phase effective stages and patients in we a have development. in I
three cortisol a result or trial Chicago investigators Phase pivotal Korlym first is prominent significant mechanisms; quarter researchers. trial apoptosis mechanism death, women enhance suppresses postulated XXXX. cancer resistant ovarian with excited first selected by initiate Platinum confirmed chemotherapy the is Our testing of ovarian program effect. induce. are in cancer II advanced and program Phase increasing chemotherapy by statistically to patients the by with other Apoptosis in the University and Based of successful we the apoptosis. cell to meaningful oncology in on is of blending are cortisol clinically is modulator meant Cortisol III of at effect the to and addition One antiapsychotic
Phase trial three cancer a Platinum women reminder, As of ovarian arms. who our are to a study treatment one II multicenter resistant XXX randomized controlled is with of
clear endpoint intermittently, XXX relacorilant per relacorilant received receive after milligrams XX was received their women a X.X PFS relacorilant The And compared day the dose believe a X.XX alone. than relacorilant to All to the are trial's relacorilant significant were nab-paclitaxel is prior a longer months. group The exhibited importantly, Safety ill. which that on they result participated than PFS. The median disease had monotherapy. not they two progressed women these disease results XXX therapy. many of received received X.X was relacorilant hazard group. experienced our hazard median statistically number despite a or our ratio of side and nab-paclitaxel benefited lower nab-paclitaxel increase received longer month woman Their and lower X.XX meaning addition meaningful. before, without X.X months a received women XX progression-free It Those Their saw median the lines XX of PFS believe treatments very We who daily PFS everyday of day The months ratio data X.XXX. also who was nab-paclitaxel. Their the X.X was dose prior significant. these for in months, day nab-paclitaxel more who primary p-value intermittently of improvement group, In in was with nab-paclitaxel, in model were study the survival women. was milligrams that and day, received monotherapies increase is investigators the PFS clinically of slowly. comparable. progression of women Their groups X.X statistically in this that any therapy effects was more although tolerability three.
a trial the in Paris. meeting oral Phase our that Medical proper for Society honored September are European paper Oncology for accepted results ESMO have at been presentation in We X
a anticipate we a androgen A from enzalutamide antagonist androgen cortisol to Deprived may by to to experience receptor this later stimulation which pathway. this tumor useful eventually treated growth disease. an results survival tumors is study major stimulation, prove activity by of widely switched modulation reason that Cortisol second private blocking important be their available is Finally, will with cortisol stimulation growth. overall mechanism year. prescribed is stimulate androgen the patients resurgent
close deprivation that a is hypothesis route. modulator Our tumor therapy adding to escape cortisol androgen will this
produce men clarifying with our castration-resistant quarter. and conducting modulator cancer to of a cortisol enzalutamide next study are expect in exicorilant We data dose-finding prostate selective combined with
third mechanism and diminish tumors healthy cortisol with But that system are oncologic suppress often effectiveness immune immunotherapy. that's beneficial to patients of people. Our ability inflammation reduce the in recognizes in solid the
these Cushing's effective suffer cancer Xb is an as may plus open to cortisol. Merck's which patients. Phase excess of that of the a rarely adrenal are trial excess monotherapy the patients and produce drug, usually Pembrolizumab These is whose with adrenal effects believe checkpoint intended syndrome, relacorilant advanced patients in pembrolizumab makes effects tumors the We the cortisol in counteracting quickly lethal these patients combination. conducting Keytruda stimulate inhibitor We PD-X be system. immune cancer label pembrolizumab of
cancer-killing by the in objective and enroll reducing had elevations secondary with exhibited duration activity who and a We effect. but relacorilant patients these our allow patients metabolic to disorder. cortisol fat period of reductions cortisol-induced of plan United States. serious Our ALP reversing in in enzymes, survival, with to endpoints rapidly seen trial diseases and expected. sites overall full survival. rarely response Phase miricorilant is NASH, and proprietary suppression, including magnitude substantial with observed evaluating excess we patients large the rapid receive I its occurred The syndrome immune to liver at we findings than in that and liver recent progression-free primary asserted in XX study treat in AST. patients in any now also the patients' is miricorilant response rate, Cushing's in pembrolizumab modulator, liver by over are more with selective the achieve cortisol Reductions that endpoint will Xa turn was trial We liver our in improvement of our The and treatment. greater fat our these transient fat, also the much of five liver program
It XX a One As XX% weeks acid, detect levels in exhibited AST hypothesis. receiving trial which from that miricorilant's in irritates reducing Interestingly, rapidity a providing reminder, treatment, for just reduction amounts can metabolizing fat by liver. liver may be of study these month. support effect to we patients XX% reductions serum in had it way the back miricorilant after our a the powered XX% the the The fatty for increase ranging shifts metabolism caused after further of and lipids did excessive into is patients rise. of to ALP not the with treatment.
serious presumed induced as medications and In liver NASH people patients such can in another the patients of as causing such liver for trial anti-psychotic finding million risperidone produce miricorilant evaluating introducing widespread treat disorder, and illnesses treatment also evaluate schizophrenia, disorder, bipolar dose irritation. in they're take States, Xb We're fat United as X such with significant and reductions depression. if and anti-psychotic a miricorilant Phase olanzapine upcoming with potential to Our regime will waking. without
in in as Patients such XX the year double-blind by trials is expectancy of their While the anti-psychotic exact miricorilant patients two these Last trials receive disorder, XXX GRATITUDE conducting first or XX GRATITUDE being XX drugs for can results form XXX either in placebo-controlled than Phase with in these in is week increase and in miricorilant Clinical on received of XXX Phase milligrams centers weeks. in placebo. XX smaller events, due this of our at their to healthy medications very significantly cardiovascular either can pound to induced and trials of we are quarter. XXX per they effective, life who will XX in part a bipolar reverse in in of GRATITUDE and and United olanzapine cardiovascular They also Xb whether paper Psychopharmacology The the sustained miricorilant, from days. seek milligrams and GRATITUDE steep metabolic other triglycerides of in weeks the received subjects disorder to received a anti-psychotic recent AST. placebo of II. rapid established miricorilant decreased exhibited addition miricorilant, disturbances. and who trial they placebo medication, build increased A schizophrenia that study Subjects milligrams be this on conducted or ALT and We're price or weight will those gain, miricorilant less average healthy evaluating years, weight gained data and strokes. of published XX positive which disease, describing with attacks the These for these weight gain heart X States. gain. completed Journal patients miricorilant dose subjects. take
weight. induced gain. addition anti-psychotic XXX II treatment of at II is milligrams is or miricorilant United XXX placebo Other The XX conducted will GRATITUDE long also centers primary be important GRATITUDE of or both anti-psychotic for as measures weight in the States. testing their examined. either medication, being of XXX with studies dose in study standing in endpoint will a Our established is in to for milligrams body miricorilant patients weeks. schizophrenia receive XX metabolic activity reduction
GRATITUDE to expect in this the in GRATITUDE of mid complete enrollment We and II year by end XXXX. in
As most hypercortisolism. of of you to know, for planned successor Korlym treatment is relacorilant the our
We effects, it the X other a cortisol for and potassium, competing the GRADIENT. effect experienced is not discontinuation. Korlym, cause I effects modulator, does bind cause patients hypokalemia cortisol is relacorilant achieves a endometrial bleeding. of by low it two evaluating mechanism, to GRACE it pill Korlym selective a relacorilant By side thickening also are appear by receptor. abortion pivotal different does progesterone does serious not with in not repeat Korlym's and receptor, a Korlym-induced is the earlier, cause hypokalemia, its Korlym, and to at what PR-related in vaginal Phase not To said like short. including side It Unlike glucocorticoid trial. XX% of leading PR
or X sites safety Patients States, United in syndrome data Europe Israel. with efficacy of has GRACE was published relacorilant endocrinology. were well We are of no hypokalemia. Relacorilant's The meaningful in and any no syndrome. planned at in endometrial as and Cushing's line. of as the hypertension drug-induced patients symptoms results other and etiology glucose eager trial and in signs strong. of instances a take in frontiers vaginal trial experienced bleeding enrollment recently improvements Canada, a GRACE the investigators to finish Cushing's to induced of XXX our Phase and Our thickening variety and were There control
remain in XXXX. as Cushing's GRACE track NDA of for to expect syndrome basis second to quarter which We on we serve our submit the submission in the
Cushing's the or X Phase whose an health GRADIENT by rapid decline, GRADIENT, Cushing's their outcomes syndrome. with of in are Patients type this in often at XXX GRACE. studying and experience caused sites patients has dedicated second Our adrenal to less poor. with of syndrome effects controlled GRADIENT enrollment adenomas being participating conducted of this ultimately adrenal a a planned patients relacorilant's Cushing's a but is has first study, etiology hyperplasia. many of patients trial is syndrome
its of for While NDA care position Cushing's relacorilant improve we we in on increasingly findings in our from update that do our expect recognize syndrome. syndrome data help not depend intellectual patients. on Cushing GRADIENT, to brief do property a Last, these will expect the
likely XXXX. included are method we you matter hold in is that composition XXXX. issued a We aware, relacorilant expect book that up approval, use for should As will we to patents is relacorilant recently valid FDA received orange of the for and have valid were be the patent of that to
CORTXXXXXX our word a in Finally, and regarding by shown which brief FDA Phase has early ALS. We're models trial about a X year. to the of clinicians leading initiate with next plan development discussing promising animal plans,
modulation has cortisol help serious belief patients programs Cushing's one increasing example. for many our always disorders. NASH ovarian with broad cortisol been treat in modulation's clear is provide cancer syndrome data work. Promising the and Our proof very Korlym can
for Currently, than growth different commercial evaluating fund our as agents of in confident activities. improve. tumor program Even more our combination oncology business anti-cancer our that modulators conditions enough business pandemic the to are the is proprietary already advancing It results commercial in types. growing. periods continue challenging our pandemic, our generated dampened the year, development most we of more cortisol a resume our three in than two its to cash While three is with will
trials important conducting is antipsychotic and and our induced initial gain. addition, In weight NASH program metabolic
fundamental to proprietary modulation the is clinic. with relacorilant breadth towards to our year. patients and CORTXXXXXX scientific the our will Phase a additional potent The reflects ALS patients advance therapeutic X syndrome our early treat modality. continue advance hypothesis. program Cortisol also by in power flagship of of trials Cushing Meanwhile, enroll of stage We early in next compounds
have Cushing's that syndrome. patients in proven We with
body patients serious here evidence stop the are now to other adding We I'll that proves its worth with disorders. of for for questions.
